Other Novo Nordisk and OpenAI forge alliance to drive speedy drug development Pharmaceutical TechnologyNovo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.OtherRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Technology Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025. OtherRead full story Post navigation Previous: Revolution rockets on strong pancreatic cancer dataNext: Travere claims first FDA OK in rare kidney disease FSGS Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
